Companies pursue souped-up IL-2 candidates, undeterred by Nektar’s setback.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies
Molecular Cancer Open Access 29 July 2023
-
Evaluation of the clinical molecule anti-human-PD-L1/IL-15 KD033 in the human-PD-1/PD-L1-expressing murine model demonstrates PD-L1 targeting of IL-15 in vivo
Cancer Immunology, Immunotherapy Open Access 01 December 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dolgin, E. IL-2 upgrades show promise at ASCO. Nat Biotechnol 40, 986–988 (2022). https://doi.org/10.1038/s41587-022-01390-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-022-01390-3
This article is cited by
-
Molecular Engineering of Interleukin-2 for Enhanced Therapeutic Activity in Autoimmune Diseases
BioDrugs (2024)
-
Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies
Molecular Cancer (2023)
-
Strategies to therapeutically modulate cytokine action
Nature Reviews Drug Discovery (2023)
-
Evaluation of the clinical molecule anti-human-PD-L1/IL-15 KD033 in the human-PD-1/PD-L1-expressing murine model demonstrates PD-L1 targeting of IL-15 in vivo
Cancer Immunology, Immunotherapy (2023)